Evidence map›Paper›PMID 42716976›Full record

ArticleScientific reports2026

Integrated experimental and computational evaluation of atractylenolide III from Tubipora musica for anticancer lead identification.

Hamada A A Noreldeen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hamada A A NoreldeenNational Institute of Oceanography and Fisheries, NIOF, Cairo, Egypt. haali8651@gmail.com.ORCID 0000-0001-7093-2426

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) remains a major global health challenge, with over 900,000 new cases annually and a pronounced male predominance. In pursuit of novel, low-toxicity therapeutics, this study isolated Atractylenolide III from the marine coral Tubipora musica and demonstrated measurable, dose-dependent cytotoxic activity against HepG2 liver cancer cells, achieving an IC

Indexed as

AnthozoaAntineoplastic AgentsCarcinoma, HepatocellularLactonesLiver NeoplasmsSesquiterpenesAnimalsCell SurvivalHep G2 CellsHumansMolecular Docking SimulationMolecular Dynamics SimulationPharmacophoreAntineoplastic Agentsatractylenolide IIILactonesSesquiterpenesADMETAtractylenolide IIIComputational drug designCytotoxic activityLiver Cancer (HepG2)Molecular dockingTubipora musica

Identifiers

PMID42716976
PMCPMC13558756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.